Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 4166–4168.

https://doi.org/10.1182/blood-2022-167314

Published: 2022

Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137655

Published: 2020

Journal Articles

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Nyla A. Heerema, Corinne Hoffman, Gerard Lozanski, Kami J. Maddocks, Mollie E. Moran, Mark A. Reid, Margaret Lucas, Jennifer A. Woyach, W. Thomas Whitlow, Jeffrey A. Jones, John C. Byrd

Blood (2018) 132 (15): 1568–1572.

https://doi.org/10.1182/blood-2018-05-853564

Published: 2018

Includes: Supplemental data

Journal Articles

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

Kami Maddocks, MD, Rosa Lapalombella, PhD, Kristie A Blum, MD, William Blum, MD, Beth B. Fischer, Natarajan Muthusamy, PhD, Mollie E. Moran, Donna Holtzapfel, NP, John C. Byrd, Amy J. Johnson, PhD, Leslie Andritsos, MD,

Blood (2009) 114 (22): 3446.

https://doi.org/10.1182/blood.V114.22.3446.3446

Published: 2009

Journal Articles

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson, Eunju Hurh, Darlene M. Rozewski, Katherine L. Farley, Di Wu, Kristie A. Blum, Beth Fischer, Sarah M. Mitchell, Mollie E. Moran, Michelle Brooker-McEldowney, Nyla A. Heerema, David Jarjoura, Larry J. Schaaf, John C. Byrd, Michael R. Grever, James T. Dalton

Blood (2009) 113 (12): 2637–2645.

https://doi.org/10.1182/blood-2008-07-168583

Published: 2009

Journal Articles

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Beth Fischer, BSN, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Mollie E. Moran, MSN, CNP, Sarah Mitchell, Amy J. Johnson, PhD, Mitch A. Phelps, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2008) 112 (11): 46.

https://doi.org/10.1182/blood.V112.11.46.46

Published: 2008

Journal Articles

Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, BSN, RN, Kristie A. Blum, MD, Pierluigi Porcu, MD, Eric H. Kraut, MD, Robert A. Baiocchi, MD, PhD, Mollie E. Moran, MSN, CNP, Sarah Mitchell, Michael R. Grever, MD, John C. Byrd, MD

Blood (2008) 112 (11): 1571.

https://doi.org/10.1182/blood.V112.11.1571.1571

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Margaret S. Lucas, PA-C, Nyla A. Heerema, PhD, Jennifer J. Matkovich, BS, Mollie E. Moran, CNP, Carolyn Cheney, BS, David M. Lucas, PhD, Donn C. Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2841.

https://doi.org/10.1182/blood.V108.11.2841.2841

Published: 2006

Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2845.

https://doi.org/10.1182/blood.V108.11.2845.2845

Published: 2006

Journal Articles

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Gerard Lozanski, MD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 302.

https://doi.org/10.1182/blood.V108.11.302.302

Published: 2006

Journal Articles

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Mollie E. Moran, RN, CNP, Maureen M. Buckner, RN, CNP, Roshini Shank, BS, Eric H. Kraut, MD, Pierluigi Porcu, MD, Sherif S. Farag, MD, PhD, Charles F. Eisenbeis, MD, PhD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2005) 106 (11): 944.

https://doi.org/10.1182/blood.V106.11.944.944

Published: 2005

Journal Articles

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

Mollie E. Moran, MSN, Beth Fischer, MSN, Sara Broering, BS, Kristie A. Blum, MD, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Michael R. Grever, MD, Michelle Brooker-McEldowney, MSN

Blood (2005) 106 (11): 2124.

https://doi.org/10.1182/blood.V106.11.2124.2124

Published: 2005

Journal Articles

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif S. Farag, John C. Byrd

Blood (2005) 105 (1): 289–291.

https://doi.org/10.1182/blood-2004-02-0651

Published: 2005

Journal Articles

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, David M. Lucas, PhD, Roshini S. Shank, BA, Eric H. Kraut, MD, Sheriff S. Farag, MD, PhD, Margaret S. Lucas, PA-C, Alexander D. Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 2492.

https://doi.org/10.1182/blood.V104.11.2492.2492

Published: 2004

Journal Articles

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Thomas S. Lin, MD, PhD, Sabyasachi Biswas, PhD, Louie Naumovski, MD, PhD, Phillip Lecane, PhD, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Andrew P. Mone, MD, PhD, David M. Lucas, PhD, See-Chun Phan, MD, Richard A. Miller, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3486.

https://doi.org/10.1182/blood.V104.11.3486.3486

Published: 2004

Journal Articles

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

John C. Byrd, MD, Thomas S. Lin, MD, Phd, James T. Dalton, PhD, Di Wu, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, Kristie A. Blum, MD, Roshini S. Shank, BA, David M. Lucas, PhD, Margaret S. Lucas, PA-C, Jose-Ramon Suarez, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 341.

https://doi.org/10.1182/blood.V104.11.341.341

Published: 2004

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Jennifer Swenor, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Carolyn M. Cheney, MS, David M. Lucas, PhD, Donn Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3469.

https://doi.org/10.1182/blood.V104.11.3469.3469

Published: 2004

NARROW

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only